Literature DB >> 26518421

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

S Salvi1, V Conteduca2, G Gurioli3, D Calistri3, V Casadio3, U De Giorgi2.   

Abstract

In the last few years, the presence of single nucleotide polymorphisms (SNPs) has been investigated in many tumors as predictor of disease aggressiveness and clinical outcome. We searched for relevant articles from 1998 to 2015 about the impact of SNPs in prostate cancer. Particularly, in this article, we review the pathogenetic, prognostic and predictive significance of gene polymorphisms in prostate tumor, providing a brief overview of studies in which the possible role of genetic variants was investigated in clinical settings. Because conflicting results often emerge about the impact of gene polymorphisms in prostate cancer, further larger studies are warranted in order to introduce gene polymorphism into clinical practice as biomarkers.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26518421     DOI： 10.1007/s40291-015-0169-9

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


  105 in total

1.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

2.  Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer.

Authors:  Carlos Alvarado; Lenore K Beitel; Kanishka Sircar; Armen Aprikian; Mark Trifiro; Bruce Gottlieb
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

Review 3.  Molecular basis of androgen insensitivity.

Authors:  A O Brinkmann
Journal:  Mol Cell Endocrinol       Date:  2001-06-20       Impact factor: 4.102

4.  Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.

Authors:  Sana Sfar; Elham Hassen; Hamadi Saad; Faouzi Mosbah; Lotfi Chouchane
Journal:  Cytokine       Date:  2006-09-05       Impact factor: 3.861

5.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

6.  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.

Authors:  Robert W Ross; William K Oh; Wanling Xie; Mark Pomerantz; Mari Nakabayashi; Oliver Sartor; Mary-Ellen Taplin; Meredith M Regan; Philip W Kantoff; Matthew Freedman
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

Review 7.  An overview on 5alpha-reductase inhibitors.

Authors:  Saurabh Aggarwal; Suresh Thareja; Abhilasha Verma; Tilak Raj Bhardwaj; Manoj Kumar
Journal:  Steroids       Date:  2009-10-30       Impact factor: 2.668

Review 8.  The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.

Authors:  Helmut Bonkhoff; Richard Berges
Journal:  Eur Urol       Date:  2008-11-06       Impact factor: 20.096

9.  Genetic association of the KLK4 locus with risk of prostate cancer.

Authors:  Felicity Lose; Srilakshmi Srinivasan; Tracy O'Mara; Louise Marquart; Suzanne Chambers; Robert A Gardiner; Joanne F Aitken; Amanda B Spurdle; Jyotsna Batra; Judith A Clements
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

10.  SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness.

Authors:  Hui-Yi Lin; Ernest K Amankwah; Tung-Sung Tseng; Xiaotao Qu; Dung-Tsa Chen; Jong Y Park
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240
View more
  1 in total

Review 1.  Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.

Authors:  Min Liu; Hongzhe Shi; Jiaqing Yan; Yuan Zhang; Yinglin Ma; Kaidi Le; Zhongdong Li; Nianzeng Xing; Guohui Li
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.